참고문헌
- J.B. Cha, G.Y. Ryu(2013), The Relationship among Internal Marketing Activities, Job Satisfaction, Organizational Commitment, and Turnover Intention in Pharmaceutical Companies -Focusing on Pharmaceutical Salespeople-, The Korean Journal of Health Service Management, Vol.7(1);69-82. https://doi.org/10.12811/kshsm.2013.7.1.069
- Employment Trends in the Health Industry in Q1(2018), KHIDI Korea Health Industry Development Institute, pp.7-9
- E. Bae, S. Park, M. Lee(2019), Mediating Effects of Job Crafting on Relationship between Self-Leadership and Commitment to Change for Medical Representatives in a Pharmaceutical Company, Korea Lifelong Education and HRD Institute, Vol.15(2); 125-127 https://doi.org/10.35637/klehrd.2019.15.2.006
- H.S. Im(2016), Sales and Marketing Strategies of IMD (Incrementally Modified Drugs) Cilostazole, Chungang University Master's degree, pp.13-23.
- T. Blackshear, R. Plank(1994), The Impact of Adaptive Selling on Sales Effectiveness Within the Pharmaceutical Industry, Journal of Marketing Theory and Practice, Vol.2(3);106-125. https://doi.org/10.1080/10696679.1994.11501662
- C.H. Jung, C-Y. Park, K-J. Ahn, N-H. Kim, H-K. Jang, M-K. Lee, J-Y. Park, C-H. Chung, K-W. Min, Y-A. Sung, J-H. Park, S.J. Kim, H.J. Lee, S.W. Park(2015), A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise, Diabetes/Metabolism Research and Reviews, Vol.31(3);295-306. https://doi.org/10.1002/dmrr.2613
- E. Sanchez-Rangel, S.E. Inzucchi1(2017), Metformin: clinical use in type 2 diabetes, Diabetologia, Vol.60(9);1586-1593. https://doi.org/10.1007/s00125-017-4336-x
- J.A. Hirst, A.J. Farmer, A. Dyar, T.W.C. Lung, R.J.Stevens(2013), Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis, Diabetologia, Vol.56(5);973-984. https://doi.org/10.1007/s00125-013-2856-6
- D.S. Hsia, O. Grove, W.T Cefalu(2017), An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus, Current Opinion in Endocrinology, Diabetes and Obesity, Vol.24(1);73-79.
- W.L. Bennett, N.M. Maruthur, S. Singh, J.B. Segal, L.M. Wilson, R. Chatterjee, S.S. Marinopoulos, M.A. Puhan, P. Ranasinghe, L. Block, W.K. Nicholson, S. Hutfless, E.B. Bass, S. Bolen(2011), Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations, Annals of Internal Medicine, Vol.154(9);602-613. https://doi.org/10.7326/0003-4819-154-9-201105030-00336
- S.M. Hong, C.Y. Park, D.M. Hwang, K.A. Han, C.B. Lee, C.H. Chung, K.H. Yoon, J.O. Mok, K.S. Park, S.W. Park(2017), Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension, Diabetes, Obesity and Metabolism, Vol.19(5);654-663. https://doi.org/10.1111/dom.12870
- E. Bosi, F. Dotta, Y. Jia, M. Goodman(2009), Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus, Diabetes, Obesity and Metabolism, Vol.11(5);506-515. https://doi.org/10.1111/j.1463-1326.2009.01040.x
- M. Jadzinsky, A. Pfutzner, E. Paz-Pacheco, Z. Xu, E. Allen, R. Chen(2009), Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial, Diabetes, Obesity and Metabolism, Vol.11(5);611-622. https://doi.org/10.1111/j.1463-1326.2009.01056.x
- P-H. Groop, S. Del Prato, M-R. Taskinen, D.R. Owens, Y. Gong, S. Crowe, S. Patel, M. von Eynatten, H-J. Woerle(2014), Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment, Diabetes, Obesity and Metabolism, Vol.16(6);560-568. https://doi.org/10.1111/dom.12281
- H.J. Kim, Y.S. Kim, C.B. Lee, M-G. Choi, H-J. Chang, S.K. Kim, J.M. Yu, T.H. Kim, J.H. Lee, K.J. Ahn , K. Kim, K.W. Lee(2019), Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report, Diabetes Therapy Vol.10(4);1271-1282. https://doi.org/10.1007/s13300-019-0628-0
- N. Gu, M.K. Park, T-E. Kim, M.Y. Bahng, K.S. Lim, S-H. Cho, S.H. Yoon, J-Y. Cho, I-J. Jang, K-S. Yu(2014), Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers, Drug Design, Development and Therapy, Vol.8;1709-1721. https://doi.org/10.2147/DDDT.S65678
- M-K. Kim, Y.N. Chae, G-J. Ahn, C.Y. Shin, S-H. Choi, E.K Yang, Y.S. Sohn, M-H. Son(2016), Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models, Archives of Pharmacal Research, Vol.40(2);268-281. https://doi.org/10.1007/s12272-016-0864-z
- H.K. Lee, M-K. Kim, H.D. Kim, H.J. Kim, J.W. Kim, J-O. Lee, C-W. Kim, E.E. Kim(2017), Unique binding mode of Evogliptin with human dipeptidyl peptidase IV, Biochemical and Biophysical Research Communications, Vol.494(3-4);452-459. https://doi.org/10.1016/j.bbrc.2017.10.101
- I-S. Choi(2009), Two Perspectives on Facilitation in Adult Education: Learner-centered Facilitation versus Interventionist Facilitation, Andragogy Today : International Journal of Adult & Continuing Education, Vol.12(3);103-129.
- C.J. Choi, J.M. Kim, Y.G. Park(2004), Patient-Centered Attitudes and Communication Skills in Medical Students after Clerkship, Korean Journal of Medical Education, Vol.16(2);169-177. https://doi.org/10.3946/kjme.2004.16.2.169
- H.S. Im(2018), Site of Pharmaceutical Bio Industry, Naeha publishing company, pp.204-211.